The American Cancer Society helps men with prostate cancer in every community. And we’re funding research to help find more cures and save even more lives in the future.
The American Cancer Society's Population Science department includes scientists who work with our large, on-going cancer prevention studies (CPS), such as CPS-II and CPS-3.
"Previous studies show that men with obesity may have a higher risk of developing advanced prostate cancer and of dying from it. My research team used data from the CPS-II Nutrition Cohort to see how weight increases after a diagnosis of prostate cancer affected the risk of dying. We found new evidence that men who've been diagnosed with prostate cancer should strive to maintain a healthy body weight to improve their survival." - Ying Wang, PhD
The American Cancer Society (ACS) employs a staff of full-time researchers and funds scientists across the United States who relentlessly search for answers to help us better understand cancer, including prostate cancer. Here are some highlights of their work.
"In my experience as a urologic oncologist, and from my research results, optimizing treatment of men with aggressive prostate cancer likely has to go beyond just granting basic health insurance coverage. We have to identify interventions, be it at the patient, provider, or policy level, that will break deeply ingrained barriers to providing equitable cancer care for underserved communities of people of color and those with a socioeconomic disadvantage." - Christopher Filson, MD, MS
“It is yet to be seen whether the 2018 updated USPSTF recommendations for informed decision-making for PSA-based screening for men ages 55 to 69 years will lead to an increase in PSA testing and halt or reverse the rise in late-stage prostate cancer- incidence rates.”—Ahmedin Jemal, DVM, PhD
The American Cancer Society funds scientists who conduct research about cancer at medical schools, universities, research institutes, and hospitals throughout the United States. We use a rigorous and independent peer review process to select the most innovative research projects proposals to fund.
Stats to the left are as of January 4, 2023.
Each year the American Cancer Society Surveillance & Health Equity Science team analyzes data on cancer in the United States, including prostate cancer, as part of its Cancer Statistics report in CA: A Cancer Journal for Clinicians. The report is accompanied by an educational publication, Cancer Facts & Figures.
These publications provide detailed analyses and estimates of prostate cancer incidence, survival, and mortality trends in the US. They also have the latest information on cancer risk factors, early detection, treatment, and current research.
The risk of dying from prostate cancer decreased by about 50% from the mid-1990s to the mid-2010s due to improved treatment and earlier detection through screening with prostate specific antigen (PSA) testing, which helps find cancer when it is only in the prostate (localized). But in recent years, the risk of dying from prostate cancer is only decreasing by 0.6% a year. The cause for this slowing progress may be related to changes in screening guidelines.
Despite the contribution of screening to a reduction in mortality, there was increasing evidence that PSA testing was causing undue harm through overdiagnosis and overtreatment of prostate cancer. As a result, the US Preventive Services Task Force (USPSTF) changed their screening guidelines.
In 2008, the USPSTF recommended against routine screening with PSA testing for men age 75 and older and in 2012 for all men, which led to fewer men being screened.
At first, reduced PSA testing was followed by rapid declines in the diagnosis of prostate cancer. But from 2014 to 2018, the incidence rate for local-stage disease stayed stable, whereas incidence rates for regional-stage disease rose each year by 4% and by 6% for distant-stage disease.
As a result, the proportion of prostate cancers diagnosed at an advanced stage has more than doubled over the past 10 years, from 3.9% to 8.2%.
ACS researchers note that “controversy remains about the underutilized potential of the PSA test” to reduce deaths from prostate cancer by detecting potentially fatal disease earlier.
“One study found that after the 2012 USPSTF guideline changes, there was a steeper drop in PSA testing in Black men than in White men,” says Rebecca Siegel, MPH, lead author of Cancer Statistics, 2022, and Senior Scientific Director of Surveillance Research at ACS. “That’s concerning because early detection is especially important for Black men, who are twice as likely to die from prostate cancer as White men.” See the ACS Guidelines for Screening and Early Detection of Prostate Cancer.
Find more statistics about prostate cancer on the Cancer Statistics Center:
Use the analysis tool in the drop-down menu to see any of these statistics in comparison to other types of cancer.